Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GCGR | P47871 | 14/20 | 0.51 |
| ▸ | GIPR | P48546 | 3/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081919 | 0.87 | GCGR (0.59) | GCGRGIPR | |
| SCHEMBL2663361 | 0.81 | GCGR (0.55) | LMNAGCGRGIPR | |
| SCHEMBL13800053 | 0.79 | LMNA (0.50) | LMNAGCGRGIPR | |
| SCHEMBL2663409 | 0.77 | LMNA (0.48) | LMNAGCGRGIPR | |
| SCHEMBL4082013 | 0.75 | GCGR (0.62) | LMNAGCGRGIPR | |
| SCHEMBL4086789 | 0.75 | HDAC3 (0.63) | LMNAGCGR | |
| SCHEMBL8809936 | 0.75 | HDAC1 (0.68) | HDAC1EPHX1CXCR4HRH3 | |
| SCHEMBL6481929 | 0.75 | GCGR (0.61) | LMNAGCGRGIPR | |
| SCHEMBL4081715 | 0.74 | MGAT2 (0.46) | LMNAGCGRGIPR | |
| SCHEMBL8806829 | 0.73 | HDAC1 (0.65) | HDAC1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | HDAC1 2296/4885EPHX1 2751/4885LMNA 3643/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | HDAC1 2296/4885EPHX1 2751/4885LMNA 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.